564 related articles for article (PubMed ID: 27444228)
1. Drug discovery in advanced prostate cancer: translating biology into therapy.
Yap TA; Smith AD; Ferraldeschi R; Al-Lazikani B; Workman P; de Bono JS
Nat Rev Drug Discov; 2016 Oct; 15(10):699-718. PubMed ID: 27444228
[TBL] [Abstract][Full Text] [Related]
2. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Geethakumari PR; Cookson MS; Kelly WK;
Oncology (Williston Park); 2016 Feb; 30(2):187-95, 199. PubMed ID: 26888794
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations and emerging targets in castration resistant prostate cancer.
Lorente D; De Bono JS
Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
[TBL] [Abstract][Full Text] [Related]
4. Precision medicine for advanced prostate cancer.
Mullane SA; Van Allen EM
Curr Opin Urol; 2016 May; 26(3):231-9. PubMed ID: 26909474
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
Seisen T; RouprĂȘt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
[TBL] [Abstract][Full Text] [Related]
6. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
Khanna A; Rane JK; Kivinummi KK; Urbanucci A; Helenius MA; Tolonen TT; SaramÀki OR; Latonen L; Manni V; Pimanda JE; Maitland NJ; Westermarck J; Visakorpi T
Oncotarget; 2015 Aug; 6(23):19661-70. PubMed ID: 25965834
[TBL] [Abstract][Full Text] [Related]
7. Molecular landscape of prostate cancer: implications for current clinical trials.
Khemlina G; Ikeda S; Kurzrock R
Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
[TBL] [Abstract][Full Text] [Related]
8. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer.
Nelius T; Martinez-Marin D; Hirsch J; Miller B; Rinard K; Lopez J; de Riese W; Filleur S
Cell Death Dis; 2014 May; 5(5):e1210. PubMed ID: 24810046
[TBL] [Abstract][Full Text] [Related]
9. Personalization of prostate cancer therapy through phosphoproteomics.
Yang W; Freeman MR; Kyprianou N
Nat Rev Urol; 2018 Aug; 15(8):483-497. PubMed ID: 29752463
[TBL] [Abstract][Full Text] [Related]
10. [Antisense oligodeoxynucleotide therapy for castration-resistant prostate cancer].
Miyake H; Fujisawa M
Nihon Rinsho; 2014 Dec; 72(12):2121-5. PubMed ID: 25518344
[TBL] [Abstract][Full Text] [Related]
11. The biology of castration-resistant prostate cancer.
Lian F; Sharma NV; Moran JD; Moreno CS
Curr Probl Cancer; 2015; 39(1):17-28. PubMed ID: 25547388
[No Abstract] [Full Text] [Related]
12. Development and prevalence of castration-resistant prostate cancer subtypes.
Vellky JE; Ricke WA
Neoplasia; 2020 Nov; 22(11):566-575. PubMed ID: 32980775
[TBL] [Abstract][Full Text] [Related]
13. Horizon scanning for novel therapeutics for the treatment of prostate cancer.
Bianchini D; Zivi A; Sandhu S; de Bono JS
Expert Opin Investig Drugs; 2010 Dec; 19(12):1487-502. PubMed ID: 20868208
[TBL] [Abstract][Full Text] [Related]
14. Targeted BikDD expression kills androgen-dependent and castration-resistant prostate cancer cells.
Xie X; Kong Y; Tang H; Yang L; Hsu JL; Hung MC
Mol Cancer Ther; 2014 Jul; 13(7):1813-25. PubMed ID: 24785255
[TBL] [Abstract][Full Text] [Related]
15. Towards precision oncology in advanced prostate cancer.
Ku SY; Gleave ME; Beltran H
Nat Rev Urol; 2019 Nov; 16(11):645-654. PubMed ID: 31591549
[TBL] [Abstract][Full Text] [Related]
16. The role of microRNA in castration-resistant prostate cancer.
Thieu W; Tilki D; de Vere White R; Evans CP
Urol Oncol; 2014 Jul; 32(5):517-523. PubMed ID: 24935732
[TBL] [Abstract][Full Text] [Related]
17.
Fararjeh AS; Liu YN
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
[TBL] [Abstract][Full Text] [Related]
18. Navigating the evolving therapeutic landscape in advanced prostate cancer.
Crawford ED; Petrylak D; Sartor O
Urol Oncol; 2017 May; 35S():S1-S13. PubMed ID: 28283376
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapeutic targets for patients with advanced prostate cancer.
Saad F; Shore N; Zhang T; Sharma S; Cho HK; Jacobs IA
Cancer Treat Rev; 2019 Jun; 76():1-9. PubMed ID: 30913454
[TBL] [Abstract][Full Text] [Related]
20. TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression.
Baylot V; Karaki S; Rocchi P
Results Probl Cell Differ; 2017; 64():255-261. PubMed ID: 29149413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]